The project

About the Project

NanoGSkin is a transversal research project that combines regenerative medicine technologies with nanomedicine products, in a transnational collaboration of public research groups academia, clinical/public health research sector and private companies, from 4 different countries (Spain, France, Italy and Ireland), by joining together tissue engineering, nanotechnology, biotechnology and industrial production.

NanoGSkin project aims to develop an innovative skin substitute that will overcome two of the major drawbacks of severe skin wounds: the urgent need of an effective skin implant in life-threatening situations and avoid/counteract usual bacterial infections. As a solution, NanoGSkin proposes a combination of bioengineered skin substitute incorporating nanoparticles (NPs) encapsulating antibiotics and recombinant human epidermal growth factor (rhEGF) respectively as an advanced chronic wound therapy.

Goals and objectives

The final goal of this project is to achieve a maximal rate of therapeutic success, giving response to a clinical need as are complex wounds, a major Health problem associated with an ageing population, but also burns and surgical tissue lesions.

Toward this end, the following issues will be addressed:

  • Shortening cell harvest period– by adding nanoencapsulated growth factors to the medium that will fasten cell proliferation.
  • Minimizing the grafting period– by developing a semisolid formulation that could mimic the extracellular matrix containing nanoencapsulated growth factors.
  • Decreasing the bacterial load of skin substitutes to improve grafting– by adding to the semisolid formulation nanoencapsulated antibiotics to fight against pathogens.
  • Increasing bioengineered skin shelf life– by implementing a distribution medium that could enhance its stability.
  • Testing the resulting cell and NP based formulation efficiency and safety.
  • Designing modular clean rooms to enable the application of this therapy at new centers.
  • Define a realistic exploitation and business model.

As a result, NanoGSkin product radically improves treatment efficacy by enhancing skin growth and protection against bacterial infections and allowing rhEGF and antibiotic sustained release, treatment safety due to the enhanced properties of the engineered skin and antimicrobial protection and patient compliance since it is a non-drug dependent therapy.

Work packages

  1. Manufacturing technology implementation. Optimisation of the biofabrication process of the bioengineered human skin substitute by the addition of nanoencapsulated rhEGF.
  2. Substitute implementation. Improvement of the bioengineered human skin substitute for use in patients with infected wounds by using antibiotic-loaded NPs.
  3. Efficacy studies. To carry out in vitro and in vivo studies to ensure efficacy of the NP supplemented bioengineered human skin.
  4. Nanosafety. To ensure the safety of the developed nanoformulations.
  5. Assembly and GMP scale-up. Design and manufacturing of the NP supplemented bioengineered skin under GMP or GMP-like environment.
  6. Viability, dissemination and worldwide market Access. Adequate exploitation of the results and dissemination to the relevant stakeholders by generating an adequate business model to get a fast market entrance of products and a sustainable life cycle of product.
  7. Project Coordination. Promote effective communication among members of the research consortium to enable integration of work packages.